Study of Ambrisentan in Chronic Thromboembolic Pulmonary Hypertension

• Research type

  Research Study

• Full title

  A randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)

• IRAS ID

  129156

• Contact name

  Joanna Pepke-Zaba

• Contact email

  joanna.pepkezaba@papworth.nhs.uk

• Sponsor organisation

  GlaxoSmithKline

• Eudract number

  2012-001646-18

• ISRCTN Number

  n/a

• REC name

  East of England - Cambridge South Research Ethics Committee

• REC reference

  13/EE/0167

• Date of REC Opinion

  2 Sep 2013

• REC opinion

  Further Information Favourable Opinion